background
recent
data
suggest
human
coronaviru
hcov
pneumonia
associ
signific
mortal
hematopoiet
cell
transplant
hct
recipi
investig
risk
factor
prolong
shed
intrahost
genom
evolut
may
provid
critic
inform
develop
novel
therapeut
method
retrospect
review
hct
recipi
hcov
detect
nasal
sampl
polymeras
chain
reaction
pcr
hcov
strain
identifi
use
strainspecif
pcr
shed
durat
defin
time
first
posit
first
neg
sampl
logist
regress
analys
perform
evalu
factor
prolong
shed
day
metagenom
nextgener
sequenc
mng
conduct
sampl
cycl
threshold
valu
avail
result
seventeen
patient
prolong
shed
among
avail
sampl
median
shed
durat
similar
strain
p
bivari
logist
regress
analys
suggest
high
viral
load
receipt
highdos
steroid
myeloabl
condit
associ
prolong
shed
mng
among
subject
show
singlenucleotid
polymorph
start
month
follow
onset
shed
conclus
high
viral
load
highdos
steroid
myeloabl
condit
associ
prolong
shed
hcov
hct
recipi
genom
chang
consist
expect
molecular
clock
hcov
respiratori
virus
associ
prolong
shed
higher
rate
lower
respiratori
tract
diseas
mortal
hematopoiet
cell
transplant
hct
recipi
develop
novel
therapeut
effect
infect
prevent
critic
import
especi
wellestablish
respiratori
virus
respiratori
syncyti
viru
influenza
viru
parainfluenza
virus
new
molecular
diagnost
wide
avail
similar
concern
rais
respiratori
virus
includ
human
coronaviru
hcov
addit
demonstr
frequent
prolong
shed
hcov
hct
recent
data
suggest
common
hcov
import
respiratori
pathogen
relat
signific
mortal
hct
recipi
data
host
virolog
factor
associ
prolong
shed
includ
genom
evolut
within
host
may
provid
rational
develop
antivir
therapi
variou
stage
current
lack
therefor
examin
hct
recipi
defin
viral
host
factor
associ
prolong
hcov
shed
upper
respiratori
tract
examin
evolut
viral
genom
sequenc
time
metagenom
nextgener
sequenc
mng
review
hct
recipi
hcov
detect
nasal
sampl
multiplex
respiratori
viral
polymeras
chain
reaction
pcr
fred
hutchinson
cancer
research
center
subject
requir
neg
viral
pcr
test
within
week
last
posit
virolog
test
perform
interv
consecut
posit
test
beyond
week
strain
identif
perform
use
sampl
confirm
strain
subject
identifi
cohort
supplementari
figur
first
cohort
includ
patient
whose
nasal
sampl
collect
test
clinic
purpos
respiratori
symptom
present
march
june
second
cohort
came
prospect
surveil
studi
hct
recipi
undergo
transplant
decemb
februari
standard
respiratori
symptom
survey
multiplex
respiratori
pcr
test
perform
weekli
first
day
posttranspl
everi
month
year
posttranspl
whenev
respiratori
symptom
occur
day
posttranspl
subject
respiratori
symptom
select
current
studi
duplic
subject
analyz
separ
mng
conduct
posit
sampl
cycl
threshold
ct
valu
avail
irrespect
presenc
respiratori
symptom
abovement
prospect
surveil
studi
hct
recipi
demograph
clinic
data
collect
databas
medic
chart
review
studi
approv
institut
board
review
fred
hutchinson
cancer
research
center
hcov
detect
viral
load
determin
nasal
specimen
quantit
reversetranscript
pcr
part
multiplex
pcr
use
detect
respiratori
virus
strainspecif
pcr
perform
use
save
nasal
sampl
accord
previous
publish
protocol
mng
perform
dnase
itreat
rna
extract
filter
nasal
specimen
use
tagment
transposonmedi
fragment
cdna
librari
cycl
pcr
amplif
sampl
ct
valu
avail
sequenc
read
trim
use
cutadapt
align
concaten
hcov
refer
genom
use
geneiou
version
durat
shed
defin
time
first
posit
first
neg
sampl
prolong
shed
defin
durat
shed
day
describ
median
shed
durat
hcov
first
day
hct
highest
daili
steroid
dose
lowest
cell
count
week
prior
first
hcov
detect
record
condit
regimen
categor
myeloabl
nonmyeloablativereduc
intens
base
definit
previous
describ
univari
bivari
logist
regress
analys
perform
evalu
associ
virolog
host
factor
prolong
shed
first
episod
hcov
infect
per
subject
use
outcom
analys
variabl
p
univari
model
candid
bivari
model
kruskalw
test
perform
compar
continu
valu
among
group
twosid
p
valu
consid
statist
signific
statist
analys
perform
use
sa
window
sa
institut
cari
north
carolina
identifi
hct
recipi
respiratori
hcov
infect
cohort
cohort
respect
adult
pediatr
patient
tabl
supplementari
figur
median
durat
shed
day
day
patient
prolong
shed
day
among
avail
nasal
sampl
median
shed
durat
hcov
nasal
sampl
differ
strain
figur
p
initi
high
viral
load
ct
valu
median
associ
prolong
shed
lowest
p
valu
univari
analysi
univari
bivari
logist
regress
analys
indic
initi
high
viral
load
associ
prolong
shed
consist
model
tabl
highdos
steroid
use
mgkgday
prior
hcov
diagnosi
myeloabl
condit
regimen
associ
prolong
shed
bivari
analys
four
patient
start
viral
shed
prior
transplant
therefor
separ
analyz
patient
start
shed
transplant
result
remain
similar
data
shown
whole
genom
consecut
sequenc
sampl
hct
adult
subject
pediatr
subject
sampl
avail
day
follow
first
posit
sampl
tabl
engraft
occur
patient
prior
start
shed
major
consensu
variant
recov
patient
day
onset
shed
singlenucleotid
variant
accumul
rate
approxim
variant
per
week
consist
previou
estim
hcov
molecular
clock
figur
singlenucleotid
polymorph
snp
recov
patient
respect
one
adult
patient
patient
develop
lower
respiratori
tract
diseas
set
highdos
steroid
use
acut
graftvshost
diseas
prolong
shed
bronchoalveolar
lavag
perform
day
start
shed
aspergillu
fumigatu
detect
addit
hcov
one
pediatr
patient
patient
differ
hcov
strain
detect
success
period
month
studi
demonstr
signific
associ
prolong
shed
hcov
initi
high
viral
load
transplant
recipi
addit
prior
highdos
steroid
use
myeloabl
condit
regimen
appear
associ
prolong
shed
durat
shed
appear
similar
across
hcov
strain
drastic
intrahost
evolut
viral
genom
occur
immunocompromis
popul
prolong
shed
sever
acut
respiratori
syndrom
middl
east
respiratori
syndrom
mer
coronavirus
recogn
highli
humanpathogen
coronavirus
caus
fatal
lower
respiratori
tract
diseas
howev
establish
antivir
therapi
recent
data
suggest
lower
respiratori
tract
diseas
caus
hcov
strain
also
associ
signific
respiratori
support
mortal
immunocompromis
host
unmet
need
develop
antivir
therapi
hcov
expect
expand
immunocompromis
popul
grow
found
initi
high
viral
load
prior
highdos
steroid
use
myeloabl
condit
import
factor
associ
prolong
hcov
shed
hct
recipi
durat
viral
shed
often
use
endpoint
earli
stage
clinic
trial
new
antivir
drug
stratif
base
risk
factor
critic
avoid
imbal
due
host
viral
factor
random
trial
might
otherwis
mask
true
differ
experiment
agent
genet
variabl
hcov
commun
level
intrahost
heterogen
mer
coronaviru
report
variabl
might
import
implic
viral
diseas
pathogenesi
studi
viral
genom
evolut
within
host
provid
vital
inform
import
develop
assess
antivir
agent
exampl
develop
antivir
drug
resist
individu
therapi
associ
poor
outcom
describ
extens
influenza
viru
grad
et
al
report
intrahost
genom
evolut
respiratori
syncyti
viru
time
infant
sever
combin
immun
defici
underw
bone
marrow
transplant
viral
popul
divers
dramat
increas
engraft
appear
reflect
dynam
respons
immun
pressur
host
immun
knowledg
previou
data
exist
describ
hcov
genom
evolv
within
host
time
current
studi
engraft
occur
patient
sequenc
prior
onset
shed
interestingli
snp
recov
day
onset
shed
even
immun
reconstitut
variant
accumul
start
month
onset
shed
chang
time
consist
previous
estim
evolut
rate
hcov
given
rel
slow
evolut
rate
coronavirus
observ
could
promis
standpoint
antivir
resist
therapeut
develop
due
except
larg
rna
genom
coronavirus
known
encod
highli
process
polymeras
well
proofread
exoribonucleas
temper
viral
genom
evolut
rel
rna
virus
epidemiolog
biochem
work
requir
character
function
impact
variant
recov
tabl
nonsynonym
synonym
variant
depict
rel
day
genom
recov
major
consensu
nonsynonym
chang
allel
frequenc
indict
red
major
consensu
synonym
chang
allel
frequenc
shown
green
allel
frequenc
variant
site
depict
major
allel
frequenc
nonsynonym
chang
shown
amino
acid
given
gene
synonym
chang
shown
nucleotid
gene
allel
frequenc
alon
shown
major
consensu
base
variant
rel
day
genom
major
allel
frequenc
base
flux
abbrevi
hemagglutinin
esteras
membran
protein
n
nucleocapsid
protein
main
limit
studi
rel
small
sampl
size
thu
bivari
logist
regress
analys
perform
instead
multivari
analys
evalu
risk
factor
prolong
shed
similarli
although
particular
strain
appear
associ
prolong
shed
strain
identif
use
save
sampl
success
patient
limit
abil
detect
small
differ
shed
durat
among
hcov
strain
studi
larger
sampl
size
help
clarifi
distinct
associ
particular
hcov
strain
prolong
shed
final
cohort
includ
patient
document
hcov
shed
prior
transplant
consid
unmeasur
influenc
differ
background
analys
separ
analyz
patient
start
shed
transplant
univari
logist
regress
analysi
could
perform
due
small
sampl
size
similar
result
first
studi
evalu
risk
factor
associ
prolong
shed
hcov
quantit
strainspecif
revers
transcript
pcr
well
intrahost
genom
evolut
metagenom
rna
sequenc
transplant
recipi
studi
provid
critic
inform
develop
antivir
therapi
design
random
trial
viral
load
endpoint
addit
durat
shed
import
determin
viral
infect
transmiss
predict
factor
prolong
shed
may
provid
use
inform
effect
infect
control
expect
durat
isol
studi
need
valid
risk
factor
includ
particular
hcov
strain
prolong
shed
supplementari
materi
avail
journal
infecti
diseas
onlin
consist
data
provid
author
benefit
reader
post
materi
copyedit
sole
respons
author
question
comment
address
correspond
author
